Reduction of imiquimod impurities in pharmaceutical creams

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 7928118
APP PUB NO 20100130532A1
SERIAL NO

12698113

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
MEDICIS PHARMACEUTICAL CORPORATIONSCOTTSDALE, AZ106

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Nelson, Robert J Cottage Grove, US 92 2905
Statham, Alexis S Woodbury, US 36 737

Cited Art Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (2)
2003/0026,794 Selective enzyme treatment of skin conditions 41 2001
2003/0059,471 Oral delivery formulation 155 2001
 
Minnesota Mining and Manufacturing Company (2)
4411893 Topical medicament preparations 77 1982
5346905 1-substituted 1H-imidazo-[4,5-C]quinolin-4-amines 254 1992
 
Kythera Biopharmaceuticals, Inc. (1)
2005/0201,959 Methods and compositions for altering skin coloration 31 2004
 
ALZA CORPORATION (2)
4746515 Skin permeation enhancer compositions using glycerol monolaurate 118 1987
6210712 Dosage form having first and second coats 82 1998
 
THERATECH, INC. (1)
4863970 Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols 218 1988
 
PERICOR SCIENCE, INC. (1)
6267957 Attaching agents to tissue with transglutaminase and a transglutaminase substrate 91 1999
 
GRACEWAY PHARMACEUTICALS, LLC (2)
4689338 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use 357 1985
5238944 Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine 262 1992
 
LUITPOLD PHARMACEUTICALS, INC. (1)
5919815 Taxane compounds and compositions 110 1996
 
MEPHA AG (1)
2006/0039,931 Stable cream preparations of phenyl-pyridone compounds for topical application 34 2003
 
TAKEDA PHARMACEUTICAL COMPANY LIMITED (1)
6194425 Imidazonaphthyridines 202 1998
 
CORIUM INTERNATIONAL, INC. (2)
6803420 Two-phase, water-absorbent bioadhesive composition 106 2002
2003/0170,308 Hydrogel compositions 114 2002
 
FUJIMORI KOGYO CO., LTD. (1)
4686125 Film laminate for sterile flexible containers 107 1984
 
NOVEN PHARMACEUTICALS, INC. (3)
5300291 Method and device for the release of drugs to the skin 100 1991
6562363 Bioadhesive compositions and methods for topical administration of active agents 196 1998
6638528 Compositions and methods to effect the release profile in the transdermal administration of active agents 143 2002
 
COLEY PHARMACEUTICAL GROUP, INC. (10)
5268376 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines 256 1991
5266575 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines 251 1991
5352784 Fused cycloalkylimidazopyridines 250 1993
5446153 Intermediates for imidazo[4,5-c]pyridin-4-amines 214 1994
5482936 Imidazo[4,5-C]quinoline amines 228 1995
6376669 Dye labeled imidazoquinoline compounds 185 2000
6660735 Urea substituted imidazoquinoline ethers 152 2002
6677347 Sulfonamido ether substituted imidazoquinolines 147 2002
6677348 Aryl ether substituted imidazoquinolines 147 2002
2004/0176,367 1-Amino 1H-imidazoquinolines 90 2004
 
ABB TECHNOLOGY AG (1)
2004/0089,855 High oleic acid oil compositions and methods of making and electrical insulation fluids and devices comprising the same 33 2003
 
Galenix Innovations (2)
2003/0096,012 Film-forming powder, compositions containing it, methods for their preparation and their uses 76 2002
2003/0124,191 Use of an immediate-release powder in pharmaceutical and nutraceutical compositions 69 2002
 
HENKEL IP & HOLDING GMBH (1)
2002/0128,345 Hot melt adhesives for dermal application 39 2000
 
INTERCONNECTRON GMBH (1)
6425776 Circular plug and socket connector for producing electrical line connections 35 2000
 
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (1)
2005/0175,630 Immunogenic compositions and methods of use thereof 51 2004
 
ASTRA AKTIEBOLAG (1)
6103697 Peptides with immunomodulatory effects 35 1997
 
3M INNOVATIVE PROPERTIES COMPANY (25)
6039969 Immune response modifier compounds for treatment of TH2 mediated and related diseases 245 1997
6110929 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof 208 1999
6245776 Formulations and methods for treatment of mucosal associated conditions with an immune response modifier 243 2000
6200592 Immine response modifier compounds for treatment of TH2 mediated and related diseases 113 2000
6331539 Sulfonamide and sulfamide substituted imidazoquinolines 200 2000
6451810 Amide substituted imidazoquinolines 179 2000
6656938 Urea substituted imidazoquinoline ethers 153 2001
6660747 Amido ether substituted imidazoquinolines 148 2001
6664260 Heterocyclic ether substituted imidazoquinolines 142 2001
6664264 Thioether substituted imidazoquinolines 153 2001
6670372 Aryl ether substituted imidazoquinolines 147 2001
6683088 Sulfonamido ether substituted imidazoquinolines 147 2001
6756382 Amide substituted imidazoquinolines 120 2001
6525064 Sulfonamido substituted imidazopyridines 171 2002
6545016 Amide substituted imidazopyridines 167 2002
6545017 Urea substituted imidazopyridines 167 2002
6664265 Amido ether substituted imidazoquinolines 153 2002
6667312 Thioether substituted imidazoquinolines 152 2002
2003/0199,538 Pharmaceutical formulation comprising an immune response modifier 114 2002
6677349 Sulfonamide and sulfamide substituted imidazoquinolines 149 2003
6797718 Ether substituted imidazopyridines 117 2003
2004/0091,491 Immunostimulatory compositions and methods of stimulating an immune response 100 2003
6818650 1H-imidazo dimers 117 2003
2004/0132,766 1H-imidazo dimers 56 2003
2004/0147,543 Aryl substituted imidazoquinolines 95 2003
 
CRESCITA THERAPEUTICS INC. (1)
2005/0276,842 Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same 75 2005
 
Nippon Oil and Fats Co., Ltd. (1)
4601856 Method of purifying oleic acid 35 1985
 
MEDICIS PHARMACEUTICAL CORPORATION (7)
5389640 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines 285 1992
5736553 Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo?4,5-C!quinolin-4-amine 71 1995
5939090 Gel formulations for topical drug delivery 205 1996
6541485 Urea substituted imidazoquinolines 161 2000
6573273 Urea substituted imidazoquinolines 155 2001
2004/0192,585 Treatment for basal cell carcinoma 87 2004
2007/0167,479 Immune response modifier formulations and methods 63 2005
 
AGIS INDUSTRIES (1983) LTD. (1)
2006/0034,779 Foamable compositions containing vitamin D3 analogues, processes for preparing same and methods of treatment utilizng same 35 2005
 
The Procter & Gamble Company (1)
5008110 Storage-stable transdermal patch 119 1988
 
Warner-Lambert Company (1)
4908389 Penetration enhancement system 58 1986
 
SHISEIDO COMPANY, LTD. (1)
5472982 Emulsified external treatment composition containing diclofenac sodium 31 1993
 
Riker Laboratories, Inc. (4)
4751087 Transdermal nitroglycerin delivery system 104 1985
4698348 1H-imidazo[4,5-c]quinolines and their use as bronchodilating agents 285 1985
4929624 Olefinic 1H-imidazo(4,5-c)quinolin-4-amines 294 1989
5756747 1H-imidazo?4,5-c!quinolin-4-amines 213 1995
 
COGNIS CORPORATION (1)
6498261 Process for improving color and color stability of oleic acid 31 1995
 
DERMATRENDS, INC. (1)
2003/0072,814 Topical pharmaceutical composition for the treatment of warts 95 2002
 
LTS LOHMANN THERAPIE-SYSTEME AG (1)
7056528 Transdermal therapeutic system containing tulobuterol hydrochloride for administering the bronchodilator tulobuterol via the skin 35 2000
 
Hisamitsu Pharmaceuticals (1)
7504114 Preparations for percutaneous absorption 36 2000
 
Purcell Jojoba International, LLC (1)
6559182 Method for treatment of enveloped viruses using jojoba oil esters 33 2001
 
VIRUN, INC. (1)
2005/0281,772 Compositions for mucosal delivery of agents 71 2005
 
PERRIGO ISRAEL PHARMACEUTICALS LTD. (1)
2006/0024,243 Foamable compositions containing nitro-imidazoles, processes for preparing same and methods of treatment utilizing same 31 2005
 
RANBAXY LABORATORIES LIMITED (1)
2005/0037,030 Stable topical formulation of clarithromycin 30 2004
 
TAKEDA CHEMICAL INDUSTRIES, LTD. (1)
4695465 Soft patch 129 1985
 
A.V. TOPCHIEV INSTITUTE OF PETROCHEMICAL SYNTHESES, RUSSIAN ACADEMY OF SCIENCES (1)
2004/0242,770 Covalent and non-covalent crosslinking of hydrophilic polymers and adhesive compositions prepared therewith 73 2004
 
PHARMACIA & UPJOHN COMPANY (1)
2003/0211,163 Combination antiviral therapy 40 2003
 
MITSUI CHEMICALS, INC. (1)
5532030 Polyolefin multilayer laminate, vessel and packaging material 71 1995
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (1)
9980955 Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts 0 2015
 
MEDICIS PHARMACEUTICAL CORPORATION (6)
* 2010/0160,368 Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy 6 2009
* 2011/0207,766 LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS 3 2010
8598196 Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy 0 2012
8642616 Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts 1 2012
9271973 Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy 0 2013
9078889 Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts 2 2013
* Cited By Examiner

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Oct 19, 2018
11.5 Year Payment $7400.00 $3700.00 $1850.00 Oct 19, 2022
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00